N
CPRX

Nuveen’s Catalyst Pharmaceutical CPRX Stock Holding History

Nuveen’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Buy
419,508
+987
+0.2% +$23.5K ﹤0.01% 1525
2025
Q4 		$9.77M Sell
418,521
-123,708
-23% -$2.76M ﹤0.01% 1561
2025
Q3 		$10.7M Sell
542,229
-444,042
-45% -$9.13M ﹤0.01% 1509
2025
Q2 		$21.4M Buy
986,271
+218,259
+28% +$5.15M 0.01% 1062
2025
Q1 		$17.2M Sell
768,012
-536,379
-41% -$12.1M 0.01% 1216
2024
Q4 		$27.2M Buy
1,304,391
+165,249
+15% +$3.55M 0.01% 979
2024
Q3 		$22.6M Buy
1,139,142
+308,586
+37% +$5.72M 0.01% 1098
2024
Q2 		$12.9M Buy
830,556
+260,037
+46% +$4.05M ﹤0.01% 1422
2024
Q1 		$9.09M Buy
570,519
+301,807
+112% +$4.55M ﹤0.01% 1653
2023
Q4 		$4.52M Buy
268,712
+4,877
+2% +$66.7K ﹤0.01% 2038
2023
Q3 		$3.08M Buy
263,835
+4,631
+2% +$61.9K ﹤0.01% 2112
2023
Q2 		$3.48M Sell
259,204
-5,367
-2% -$77.2K ﹤0.01% 2089
2023
Q1 		$4.39M Sell
264,571
-661,306
-71% -$10.9M ﹤0.01% 1969
2022
Q4 		$17.2M Sell
925,877
-457,912
-33% -$7.05M 0.01% 1150
2022
Q3 		$17.8M Sell
1,383,789
-65,968
-5% -$782K 0.01% 1098
2022
Q2 		$10.2M Buy
1,449,757
+751,576
+108% +$5.51M ﹤0.01% 1498
2022
Q1 		$5.48M Sell
698,181
-30,753
-4% -$217K ﹤0.01% 2013
2021
Q4 		$4.68M Sell
728,934
-73,349
-9% -$482K ﹤0.01% 2163
2021
Q3 		$4.05M Sell
802,283
-108,682
-12% -$594K ﹤0.01% 2326
2021
Q2 		$5.24M Buy
910,965
+33,484
+4% +$173K ﹤0.01% 2221
2021
Q1 		$4.04M Sell
877,481
-39,348
-4% -$156K ﹤0.01% 2266
2020
Q4 		$3.06M Buy
916,829
+533,282
+139% +$1.79M ﹤0.01% 2295
2020
Q3 		$1.14M Buy
383,547
+1,910
+0.5% +$7.47K ﹤0.01% 2631
2020
Q2 		$1.76M Sell
381,637
-17,781
-4% -$79.9K ﹤0.01% 2392
2020
Q1 		$1.54M Sell
399,418
-1,750,115
-81% -$7.18M ﹤0.01% 2316
2019
Q4 		$8.06M Buy
2,149,533
+1,748,591
+436% +$8.18M ﹤0.01% 1720
2019
Q3 		$2.13M Buy
400,942
+6,377
+2% +$34K ﹤0.01% 2368
2019
Q2 		$1.51M Buy
+394,565
New +$1.7M ﹤0.01% 2563

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen's CPRX Position: Q1 2026 in Review

Nuveen increased its Catalyst Pharmaceutical (CPRX) stake by 0.24% in Q1 2026, buying an estimated $23.5K and bringing the position to 419,508 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

Nuveen first reported a position in CPRX in Q2 2019 and has held it in 28 quarters since. The position peaked at $27.2M in Q4 2024. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Nuveen held 419,508 shares of Catalyst Pharmaceutical worth $10.4M as of Q1 2026.
  • Nuveen bought 987 Catalyst Pharmaceutical shares in Q1 2026, an estimated $23.5K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1525 holding.
  • Nuveen first reported a position in Catalyst Pharmaceutical in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Catalyst Pharmaceutical position peaked at $27.2M in Q4 2024.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.